CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-Small Cell Lung Cancer With EGFR Common Mutations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06391944
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:34.363982+00:00
Published At: 2024-04-30T00:00:00+00:00
Record Updated At: 2024-04-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Local Advanced or Metastatic NSCLC", "Harboring EGFR Common Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-04-30"
protocolSection.identificationModule.nctId: "NCT06391944"
protocolSection.identificationModule.officialTitle: "A Phase 2, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Stage \u2162b-\u2163 Non-Small Cell Lung Cancer With EGFR Common Mutations"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.